Clinical Trials · NCT03967249
Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Enrollment
- 39
- Start date
- Jul 2019
- Locations
- 22 sites, 6 countries
- Primary endpoint
- The Incidence of Adverse Events